Astellas Pharma Inc.
Astellas Pharma Inc. (JPX: 4503) is trading at ¥2,300.50, about ₹1,404 at today's JPY/INR rate, as of 30 Sep 2026, 9:19 PM ET, down 0.86% today. Indian residents can buy Astellas Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
¥2,262.50
Today's high
¥2,319.00
52 week low
¥1,557.50
52 week high
¥2,717.00
4503 opened at ¥2,312.00, closed previously at ¥2,320.50, and has traded between ¥1,557.50 and ¥2,717.00 over the past 52 weeks.
About
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.
Key statistics
Avg. volume
6.47M
Market cap
¥4.12T
P/E Ratio
11.29
Price-to-sales ratio
1.81
Enterprise value
¥4.80T
Free cash flow yield
11.27%
Debt-to-equity ratio
0.30
Return on equity
15.92%
ROIC
12.52%
Beta
0.09
Dividend yield
3.43%
Last dividend
¥79.00
Financial overview
Revenue
¥2.14T
Earnings per share
¥162.77
Free cash flow
¥508.53B
Net profit margin
16.04%
Gross margin
74.71%
EBITDA
¥585.25B
Revenue growth
11.87%
Similar securities
This is not an investment recommendation
How to buy Astellas Pharma from India
Indian residents can buy Astellas Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to JPY.
Search for Astellas Pharma and place an order
Find Astellas Pharma by name or by its ticker, 4503, and choose an order type. The Tokyo Stock Exchange typically trades in units of 100 shares. Astellas Pharma trades 5:30 am – 12:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Astellas Pharma position in JPY and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.
Read the full guide: how to invest in Astellas Pharma from India
Trading and taxes when buying Astellas Pharma from India
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm JST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Japan withholds a preferential 10% on dividends for Indian residents under the India–Japan DTAA rather than the higher domestic rate, and the tax withheld can be claimed as a foreign tax credit in India. Astellas Pharma’s current yield is 3.43%.Dividend tax explained
- Estate or inheritance tax
- May applyJapan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Astellas Pharma stock?
Yes. Astellas Pharma (4503) has been listed on the Tokyo Stock Exchange since 1949, in the Drug Manufacturers - General industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to JPY. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Astellas Pharma share cost in rupees?
One Astellas Pharma share is ¥2,300.50 — about ₹1,404 at a JPY/INR rate of 0.6103 on 30 Sep 2026. Both the Astellas Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Astellas Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Astellas Pharma?
The Tokyo Stock Exchange typically trades in units of 100 shares.
How are gains on Astellas Pharma shares taxed in India?
Japan generally does not levy capital gains tax on non-resident individual investors, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the JPY/INR rate on the purchase and the sale date, so the rupee move counts alongside the Astellas Pharma price. Paasa issues a capital-gains statement for your return.
Does Astellas Pharma pay a dividend, and how is it taxed in India?
Yes. Astellas Pharma pays a dividend and the current yield is 3.43%; the last declared dividend was ¥79.00 per share, about ₹48.21. Dividends are taxed at your slab rate in India. Japan withholds a preferential 10% on dividends for Indian residents under the India–Japan DTAA rather than the higher domestic rate, and the tax withheld can be claimed as a foreign tax credit in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.
When can I trade Astellas Pharma from India?
The Tokyo Stock Exchange trades 5:30 am – 12:00 pm IST in Indian time. It also halts for lunch, 8:00 am – 9:00 am IST. Orders can only execute during that window.
Is there estate or inheritance tax on Astellas Pharma shares held from India?
Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. It applies to your overall holdings in that jurisdiction rather than to any one position.
Do I have to declare Astellas Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Astellas Pharma holding, its cost and its closing value.
How do I sell Astellas Pharma and bring the money back to India?
You sell during market hours (5:30 am – 12:00 pm IST) and the proceeds settle in JPY in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.